Adult & Pediatric Dermatology (ApDerm)

recent_deal_activity:

Recent activity involving ApDerm in 2025 and 2026 includes:

• Regional Expansion: In March 2026, ApDerm acquired Dermatology Professionals, Inc., which expanded its footprint into Rhode Island and North Attleboro, Massachusetts.
• Leadership Recognition: CEO Mark Lamp was named one of the "Top 60 Most Influential Healthcare Leaders" in 2025, highlighting the platform's continued focus on strategic growth and infrastructure under Waud Capital's ownership scale-community.com.
• Operational Updates: The company launched a new digital patient platform in June 2026 to improve scheduling and billing efficiency.
• Risk Management: The firm was subject to a data breach investigation in December 2025, a common hurdle for platforms of this scale.

current_ownership_status:

As of August 2026, Adult & Pediatric Dermatology (ApDerm) remains a portfolio company of Waud Capital Partners (WCP), which has backed the platform since October 2017. Mark Lamp continues to lead the organization as Chief Executive Officer in active partnership with Waud Capital Partners scale-community.com. There is currently no public evidence of a finalized sale or an active, publicized auction process; however, the platform has reached a holding period of approximately nine years, which significantly exceeds the typical 3-to-7-year private equity cycle, making it a prime candidate for a "second bite" recapitalization or exit in the near term.

likely_acquirers_or_partners:

The most likely acquirers for ApDerm include:

1. Strategic Acquirers: Schweiger Dermatology Group (backed by LLR Partners) is the most logical strategic buyer given its dominant position in the Northeast and its history of aggressive regional consolidation. Forefront Dermatology (backed by Partners Group) also maintains a significant presence in the Northeast and Mid-Atlantic, making it a strong candidate for geographic expansion.
2. Private Equity Sponsors: Given the platform's established scale and infrastructure, it is a likely target for a secondary buyout from larger healthcare-focused PE firms such as Shore Capital Partners, Ridgemont Equity Partners (owners of Anne Arundel Dermatology), or BayPine (owners of Pinnacle Dermatology), looking to merge the platform with existing holdings or initiate a new Northeast-focused growth strategy.